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INTRODUCTION 
Nosology and Etiology 
Many discrete entities have been grouped together 
as the schizophrenic or affective disorders. An anology 
for this formulation has been recent findings on mentally 
deficient patients in which the mental deficiency can be 
caused by a number of separate discrete entities, each 
of which is characterized by a distinct, genetically 
controlled, biochemical abnormality. It must be recog-
nized that the problem of schizophrenia and affective 
disorders may not be solved so sirnply and that multi-
factor or field theories of etiology may be more compat-
ible wlth the clinical and experimental data. Such 
theories imply simultaneous occurance of experiential. 
and constitutional biochemical factors in order to give 
rise to a given clinical state. 
Genetics 
The genetic studies of twins suggests a hereditary 
basis for a number of psychiatric disorders and gives 
support to biological factors in mental illness. The 
"inborn error of metabolism" and "one gene one enzyme" 
hypotheses of Garrod and Beadle upon which contemporary 
biochemical thinking is based, has achieved substantial 
-2-
support through the discovery of discrete enzymatic 
slona underlying many inherited diseases including 
mental deficiencies. However. the permanency of a detect-
Hble enzyme defect cannot be assumed because it is pos-
sible that certHi~ genetically controlled enzyme defects 
may be transient and_ occur only in response to specific 
environmental conditions or criticl::1.1 str:lges in develop-
ment. These may still give rise to permanent structural 
changes in the nervous system and in learning experience .. 
consequently giving rise to behavioral change without 
detectable enzyme abnormality. Other proponents of an 
organic etiology of schizophrenia and affective disorders 
ha.ve suggested acquired abnormali ties such as autoimmune 
resctions or viral infections. but these are not generally 
a.ccepted by contemporary investiga.tors. 1 
The Catecholamine Hypothesis 
Biochemical studies of affective disorders com-
prise an extensive literature which until recently has 
contributed little to the understanding b~ the bio-
chemical mechanisms which may underly these disorders. 
Recently. the introduction of a number of drugs capable 
of producing both profound mood changes in human 
subjects, and alterations of brain amines in animals, 
has focused interest on the possibility that a disorder 
in brain metabolism may underlie affective illness. I 
therefore will present in this thesis recent selected 
studies involving drugs affecting amine metabolism 
-3-
"ltJ"hich support the catecholamine hypothesis of affective 
disorders. This hypothesis is based on the proposal 
that depressions are related to an absolute or relative 
depletion of catecholamines at functionally important 
sites in the brain and that elations may be associated 
with an excess. Other areas of research that will be 
mentioned include the use of lithium carbonate in 
manic depressive psychosis. and carbohydra.te metabolism 
in depression. 2 
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Review of Monoamine Metabolism 
Norepinephrine is a naturally occuring catecholamine 
located in the central nervous system, the peripheral 
sympathetic fibers. and in the adrenal medulla. Both bio-
chemical and histochemical methods have demonstrated 
that norepinephrine (NEP) and the neurohumors, dopamine, 
and serotonin are concentrated in specific structures 
throughout the brain ie .• the hypothalamus, caudate, and 
lentiform nuclei. NEP functions as a neurotransmitter 
substance in the peripheral system. It has been suggested 
that NEP may function also as one of the central neuro-
transmitter substances in the brain. NEP is stored in 
granules in nerve endings and is present in body fluids. 
NEP is synthesized from tyrosine with dihydroxy-
phenylalanine (dopa) and dihydroxyphenylethylamine (dopamine) 
as the two intermediate steps. More specifically. 
tyrosine, which is plentiful in the plasma. is hydroxy-
lated to 3,4-dopa which is converted by dopa decarboxylase 
(aromatic 1 amino acid decarboxylase) to dopamine. This 
is hydrox,ylated to form NEP in the granules. The rate 
limiting step. however, is the tyrosine to dopa step. 
NEP is being continuously synthesized and broken down. 
stored and released, and various storage pools are in 
dynamic equilibrium. 3 
The breakdown of norepinephrine occurs along at 
least tvw known pathways. One involves ini tial 
oxidation by monoamine OXidase, and the other involves 
initial o-methylation by catechol o-methyl transferase. 
-5-
NEP is met~bolized inside the cell by oxidase which 
converts it to )-methKy-!+-hydroxy-mE1..ndelic acid (VNiA) 
through the intermediate metabolj_ te. :3, 4-dihydroxy-
mandelic 8.cid. Circulating NEP and NEP rele;:.,_sed by 
nerve stimlllation are metabolized to VhA by catechol 
a-methyl transferase through the intermediate metabolite 
normeta.ne phrine. 
Route of 1'1etabol1~m of E~~ineJ2hrine 
and Norepinephrine 
COhT 
: ~~:~ :~I~x:roa:d~~~~nePhrJI'l~ ~~~~~;;~~~ne 
aCidi . CONT . )-methoxy-4 ( J-methoxy- 3-methoxy-
~ .' . I\I~O ) hydroxy:-;-~ndelic 4-hydr?xy ~ 4
1
-hydroxy -
Noreplnephrlne acid (VAA) mandellc pnenyl-
(NEP)~. . -. f . aldehyde glycol t CmIT NAO /' (HHPG ) 
dopanllne 
t normetanephrine ~ conjugated 
dopa decarboxylase normetanephr1ne 
f hydroxylase 
t,yrosine 
Evidence from a large nU"lber of sources suggests 
that NEP is functionally stored in at least two different 
pools. a loosely bound t3.nd firmly bound pool. Evidence 
for th18is provided by the differential rates of 
Ur)t.9.!z,:e and release of exogenous NEP and the differential 
release of NEP and various drugs. Of particular 
relevance to the hypothesis is the suggestion that 
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reserpine releases mostly l'iJEP from the firmly bound 
store which is subsequently deaminated to s. function-
ally inactive metabolite. In addition there is a 
store of NEP which is relatively resistant to the action 
of reserpine alone, but can be released by electrical 
nerve stimulation. Both biochemical and histochemical 
studies indicate that it is difficult to deplete nerves 
of catecholamines through repeated stimulation. 
NEP is thought to be conserved by a process through 
which the nerve takes up the NEP from the synaptic area 
9nd returns it to its stores. The resynthesis and 
rebinding mechanisms are able to keep up, even with very 
rapid rates of nerve stimulation. Some investigators sug-
gest that NE? as well as dopamine and serotonin all 
function directly as trsnsmitter SUbstances while others 
postulate that one or more of them may act as modulators 
or regulators of synaptic transmission mediated by some 
other direct transmitter, for example, ACTH. Inhibition 
of either rebinding or synthesis results in catecho-
lamine depletion in nerves. The action of catecholamines, 
released by nerve stimulation is terminated in the 
synaptic area by rebinding to the cell membrane of the 
nerve end plate iNi th resul tant concentration of NEP 
ltvi thin the nerve cell. Intracellular deamination by 
MAO, within the nerve cellon the other hand, inactivates 
NEP to Vl'tIA and extrudes this inactivated form outside 
the neuron. Active NEP in the synaptic cleft free of 
the receptor site is also inactivated to normetanephrine 
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Normetanephrine (some urinary 
VNA from this source) 
(A) noradrenergic nerve ending, (B) synaptic cleft, 
(1) disch~rge of NEP into synaptic cleft. (2) reuptake 
of NEP from synaptic cleft, (3) intracellular release 
of norepinephrine from storage granules into cytoplasm 
and on tn mi tochondricl I\lAO, (4) flIAO inhi bi tor si te , 
(5) Imipramine and DIvrr site, (6) methyl dopa site. 
(7) reserpine slte.5 , 
The basis of the catecholamine hypotheSiS of 
affective disorders is that depressions are thought to 
be associated with an absolute or relative deficiency 
of catecholarnines in functional important sites in the 
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brain, and that elations may be associated with an 
excess of catecholamines. notably norepinephrine. The 
postulated pharmacological mechanisms of action of certain 
drugs give credance to this hypothesis. It has been 
shown repeatedly that high doses of reserpine markedly 
depletes NEP from the brain and causes depression in 
man,ilethargy and sedation in animals. The mechanism 
of action may involve interference with NEP storage in 
the cytoplasmic granules or at the axonal membrane 
resulting in either prevention of rebinding or release 
of NEP from its storage granule into the intracellular 
sap, thus exposing it to enzymatic attack by MAO. It 
is then metpbolized by intracellular deamination. 
Methyl dopa depletes brain NEP by acting through its 
metabolite methylnorepinephrine, which displaces NEP 
from its storage si te s. \,-Jhen conversion of methyl do pa 
to its metabolites is prevented by the appropropriate 
decarboxylase inhibitors, methyl dopa has no NEP 
depleting properties.
6 
Imipramine and desmethylimipramine (mE) prevents 
reserpine induced depression by blocking the rebinding 
or physiological uptek:e of endogenous NEP at the axonal 
cell membrane. If NEP is released by nerve stimulation. 
imipramlne acts ln such a way as to block the reuptake 
of this free NEP by the nerve. The MAO inhibitors act 
by inhibiting the intracellular deamination of NEP, thus 
increasing the amount available for extrusion to the 
receptor site.? 
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Lithium salts have been recently well established 
~s effective agents in the treatment of manic and hypo-
manic st8tes. Hhen administered prophylactically to 
patients with recurrent depressions, lithium chloride 
has been reported to decrease the frequency of attacks 
and to abolish them altogether, just as it does in 
recurrent mania. In contrast to its well-established 
direct therapeutic effect in the treatment of the 
symptomatic phase of mania, however. lithium has little 
or no direct antidepressant effect when administered 
during the symptomatic phase of depression. The postulated 
mechanism of this ion is that of increasing the intra-
neuronal deamlnation of NEP thus decreasing the NEP 
available at adrenergic receptor sites. However, in cor-
relating the clinical effects of lithium with biochemical 
findings, it is necessary to distinguish the direct 
therapeutic action of this drug in mania from its 
prophylactic action in depreSSion, since different mech-
anisms may be operative. 8 
Summary of the Pharmacological Observations 
Compatible with the Catecholamine Hypothesis 
of Affective Disorders. 
prug 
?eserpine 
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Urinary excretion patterns have also contributed 
confirmatory evidence in favor of the catecholamine 
hypothesis. Urinary excretion of normetanephrine which 
may reflect noradrenergic activity. showed a gradual 
increase during the period of definitive clinical 
improvement in depressed patients treated with imipramine. 
These findings suggest that noradrenergic activity may 
gradually increase during clinical improvement from depres-
sion, and that noradrenergic activity may be relatively 
decreased in retarded depression and increased in mania. 10 
In another study by Maas, Fawcett, and DeKirmenjian 
using carbon labeled NEP injected into the lateral vent-
ricle of a cat. it was shown that a significant fraction 
of urinary )-methoxy-4-hydroxyphenylglycol (MHPG) is 
derived from the brain pool of NEP while urinary 3-
methoxy-4-hydroxymandelic acid, metanephrlne, and perhaps 
normetanephrine, reflect catecholamine metabolism in 
peripheral adrenergic tissues. It was noted that little 
normetanephrlne enters the body pool from the brain and 
that urinary levels of NEP principally reflect the meta-
bolism of NEP by tissues other than the brain. This 
study suggests that a significant fractio:'} of (l'iIHPG) is 
derived from the brain pool of NEP, while VI1A meta-
nephrlne and normetanephrine reflect catecholamine 
metabolism in peripheral adrenergic tissue. In support 
of the catecholamine hypothesis wes the fact that there 
were no statistically significant differences between 
patients and control groups for levels of metanephrine 
or normetanephrlne in urine. It was found that the 
group· of depressed patients had significantly lower 
levels of (MHPG) in urine than did the control 
subJects. 11 
Steroid» CaLboh,ydrate and Electrolyte 
Metabolism in Depression 
In a st')dS by Curti s. Cleghorn. and Sourkes, a 
correlation was found between urinary excretion of 
adrenaline and noradrenaline. The data suggest that 
in affective states of depression, noradrenalin is 
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excreted preferentially in comparison with adrenaline 
and corticoids. while corticoids are excreted preferent-
ially in states of anxiety, ·in subjects whose difficulties 
were disorders of thinking or behavlor. 12 Results of 
oral glucose tolerance tests in a study by Herzberg, 
Copper, and Marks revealed no significant difference 
between the fasting levels of the patients tihen depressed 
and on recovery.1] 
The Use of Li thill.m Carbonate 
Nineteen years of clinical experience have shown 
lithium salts to be effective therapy for acute manic 
attacks and more recent evidence suggests that it can 
prevent recurrent psychotic depressive or manic episodes. 
Lithium's effectiveness was first observed in 1949. by 
John F. Cadet who noted that guinea pigs given lithium 
rb te b slee and letha.r.'"':-l" c .14 ca . ona ecame py . 5 He then 
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tried the compound on ten manic patients and found that 
it caused their excitement to disappear. Its action in 
acute mania has been confirmed in controlled studies 
by Schou. Gershon. Yuw'iler, and Maggs. Li thi urn was 
found to be spectfic in that it removes the hyper-
activity and elation without interfering with normal 
processes. 15 Since the work of Cade, there have been 
a number of articles tn the world literature from 
Australla. Denmark, England, France, and Russia con-
cerning the use of lithium for the treatment of manic 
behavior. 16 Of these, the enthusiastic Scandinavian 
report by Professor Schou, 1959. reviewing ten years of 
lithium therapy. endeavors to proclaim its epochal 
character. K.ingston from Canada, and particularly 
Gershon and Yuwiler. an Australian-American team, gave 
it a most notable introduction to North AmeriCa in 
1960. 17 Despite its well-demonstrated usefulness, 
lithium has not been much studied or used in the United 
States. This is due in part to the bad name that 
lithium chloride developed in 1949 when it was used 
8S a salt substitute for cardiac patients, a use that 
led to se'\.Teral deaths from lithtum poisoning. The 
introduction of tranquillzers probably further pushed 
lithium into obscurity in this country.lS 
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Reports on Manic Patients Treated with 
Lithium and Given No Other Physical Therapy 
Author 
Cade (1949) 
Despinoy and de Romeuf (1951) 
Noack aad Trautner (1951) 
Reyss ion and Grambert (1951) 
Desc 
Duc 




Schau aY1d associates (1955) 
Sivadon and Charoit (1955) 
Tev1ie and associates (1955) 
Gershon '3 Trautner (19j6) 
Ric (1956) 
associates (1958) 
Bell1. r',3: (1959) 
SC~lOU (1959) 
Ki ngsto"18 (1960) 






















































In a study by Schagenhauf t TU:Jin. and t-lhi te. Ii thlum 
carbonate was used in the treatment of ten hospitalized 
patients with acute, severe manic excitement. Patients 
were given 300 mg. four times daily until improvement 
or side effects were ap})3rent. Patients viTel'e maintained 
on 0.6 to 1.2 gm of lithium carbonate daily in divided 
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doses. The seru.lTl levels never exceeded 1.5m eq/L and 
usually were below 1.0m eq/L. As suggested by other 
investigators, additional HaCl was given because when 
given to humans, lithium causes a sodium diuresis which 
results in 51 temporary hyponatremia. All the patients 
aged 21-59. seven females and three males, had a favor-
able response to lithitoo therapy. Most had failed to 
respond satisfactorily to previous intense phenothiazine 
therapy. Improvement v~as noted usually on the fourth 
or fifth day of treatment and always before the tenth 
day. Excitement, irritability, and euphoria gave 
way to more appropriate and less irritable affective 
state, a decreased r[lte of speech and stream of thought. 
and decreased psychomotor activity. In this study 
no attempt was made to correlate serum lithium level 
and clinical improvement or tOXicity. None of the patients 
experienced any recurrence of manic illness or depressive 
sYJ'11ptoms as long as he was remained on maintainence 
therapy. Of three patients who stopped taking a main-
tainence dose, two prombtly went into acute manic 
excitement in fourteen days. 
There is evidence that in addition to controlling 
symptoms, one of the great values of lithium therapy 
is its capacity to prevent recurrences of either manic 
or deoressive symptoms when used for extended periods 
of time on maintainence dosages. Hartigan20 reported 
that he had maintained patients on dosages of lithium 
without an effect for up to six years.rhis study 
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suggested the use of lithium for learning more of the 
nature of manic depressive disorders. 21 
In a study at the New York State Psychiatric 
Institute by Warton and Fieve, a total of nineteen 
patients with manic-depressive psychosis, manic phase 
were treated with lithium between 1959 and 1965. The 
oatients selected for trec::,tment manifested hypera.ctivity. 
pressure of speech, and elation state. 22 
Psychiatric Historl of 19 Patients 
Prior manic attacks 
one 
two to five 
six to nine 





























After an observation period of ten days, the 
patients were treated with lithium carbonate for a 
two-week period at a dosage that maintained the blood 
level between 1-2 meg./liter. After this period, a 
maintaince level of 0.5 to 1.0 meg./liter was utilized. 
I 
The dosage was tapered from 1800 mg./day to 900 mg./day 
after maintainence levels were achieved. Careful 
monitoring of blood levels was done to prevent knolAm 
toxic effects. These have been elaborated by Schon,2) 
-17-
Gershon, and Maggs and include gastrointestinal upset, 
tremor, atakie. dizziness, decreased blood pressure, and 
rarely, epileptiform seizures. At high levels in vitro, 
lithium may block carbohydrate and amino acid meta-
bolism by affecting specific enzyme systems; at high 
levels in tissue culture, lithium may affect astrocyte 
met~bollsm.24 No information is available as to lithium's 
actton at these doses in man. 
In the 25 trials on 19 patients responses l;Jere 
separated into four categories: good response, equivocal 
response, inadequate trial, and poor response. 
Manic Attacks in 19 Patients Treated 
With Lithium Carbonate 
Quality of Response 
Good 








An attack W9S considered aborted when a signifi-
cant change was noted in all three parameters under 
observation. ie .. decreased motor hyperactivi ty, altered 
mood, and decreased pressure of speech. The prognosis 
and natural history of the individual manic attack are 
uncertain. Strecker cownents that "between ages 15 and 
25. the average duration is three to six months with 
future attacks in general of greater length". Noyes 
and Ke1b state the fI~verage duration of the attack is 
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six months. iI Arieti comments that "the ~)rognosis is 
almost always good, but uncertain as to recurrence.» 
In this study the shortening of the duration of the 
attack was used as the measure of efficacy and an 
unequivocal and conservative 44 percent improvement 
after two weeks on lithium was noted. If the equi-
vocal response group were included, 17 out of 25 
(68 percent) improved. Maggs used intensity of the 
symptoms of the attack as measured by the Wittenborn 
scale to evaluate the effects of lithium treatment; 
he reported his results as statistically significant 
compared with placebo in 18 out of 28 patients treated. 
Schou, in his data, demonstrated decreased frequency 
of attacks as well as the capacity to abort attacks in 
39 of 48 patients treated or approximately 80 percent 
improvement including both his "positive effect» groups 
;;>5 and "possible effect" groups.-
The impression of these investigators was that a 
closer correlation between observable body activity, social 
behavior, mood, speech, and metabolism would be needed 
to further evaluate the effects of lithium. They noted 
that the reports by Gibbons26 and Coppen of increased 
exchangeable sodium and ionic shifts as well as changes 
in electrophysiology as primary biochemical lesion or 
eDiphenomena remains open to question. 
Lithium-Mechanistic Speculations 
The site of action of lithium has been suggested 
as at the thalamic and reticular level,27 but this 
-19-
ignores any relevance to the replacement of other 
anions within the cells by lithium. It is postulated 
that the curative action of lithium may be the result 
of its intervening to reduce free energy change, through 
potassium or ~odium displacement by lithium. It may 
act through enzyme inhibition of ATP energy production 
and serve to recover lost hormonal control and direction 
of energy thus preventing an uncontrolled production 
of free energy in muscle. Lithium could be repla.clng 
intracellular fluid sodium, the loss of which helps 
to stabilize hormonal control of fluid secretion that 
otherwise fluctuates in periodic illness, the patient 
being usually polyuric at the beginning of a manic 
attack and oliguric during depression.
28 
Two reports 
seem related to such possibilities: the observation of 
Batycharya that the action of lithium is similar to the 
action of insulin in promoting a rapid uptake of glucose 
fro~ extracellular fluid into the cell, and the 6bser-
vation of Carr and SoJler that lithium has a very large 
electro-osmottc effect on water transportation in 
macrocellular experimental models and probably also in 
29 true mosaics. 
In a reViell-T of pending biochemical questions of 
lithium therapy, Greenspan (1968) cited several areas 
of observation. His studies demonstrated that in 
depression there is an increase in sodium retention 
compared with the recovered state. This is paralleled 
by an increase in 17-hydroxycorticosterold and 17-
ketosteroid levels. Such elevations were not usually 
-20-
observed in manic patients. Studies of sodium distribution 
and 24-hour exchangeable sodium in manic and depressed 
patients who responded to lithium revealed an increased 
24-hour exchangeable sodium in depression. 30 
Overton (1902) noted that if sodium were removed 
from the bath surrounding frog muscle it would no longer 
respond to electrical stimulation. Lithium was the only 
ion substituted for sodium that restored the muscle's 
excitability. Keynes and Swan (1959) demonstrated in vitro 
that lithtum moves into muscle flbers like sodium, but does 
not leave as readily. Moreover. the egress of lithium 
was not bloc\';-ed by removal of potassium which suggests 
that sodium and lithium entered alike but did not share 
the samepuf1!J mechanism for extrusipn. It vJaS found 
that lithium accumulated within muscle fiber and even-
tually rendered it inexcitable. Zerahn (1955) found 
that lithium was actively pumped across frog skin. but 
unlike sodium. accumulated in the epithelium. Similar 
findings were noted in isolated nerve observations but most 
of these were done with high concentration of lithium in 
vitro. The implication is, however, that the action of 
lithium may be due to tts effect upon sodium metabol-
. 31 Ism. 
One of the most consist~nt flndtngs has been that of 
an increase of 5~% in the amount of intracellular sodium 
together wi th a sffiEtll but unknoiJm amount of exchangeable 
bone sodium. This W2S found to return to normal after 
recovery (Coppen, 1963). Low concentrations of intra-
-21-
cellular potassium were found in depressed patients, 
but this did not alter ~ith clinical improvement (Shaw, 
Coppen. 1956). These changes are for body electrolytes 
as a whole. and there is no direct evidence that para-
lell changes take place in the central nervous system. 
If camparable events did occur in the brain, cerebral 
excitability would be much affected by reduction of both 
resting and action potentials (Shaw. Coppen, 1966). In 
addition to these changes in electrolyte distribution, 
a reduction in extracellular water in depression has 
been observed in investigations using either the 
thioc,y-anate space or the volume of radioactive bromine. 
In mania, distribution studies have revealed similar 
(but greater) changes in the distribution of sodium 
compared with those found in depression; the average 
'~2 
being twice normal. J -
Tryptamine Metabolism in Depression 
Coppen, Shaw, and Farrel (1963) showed that large 
doses of DL- tryptophan (214 mg./kg. body weight) 
given to depressed patients receiving tranylcypromine 
(a NAO inhibitor) potentiated the anti-depressive 
effects of the drug. This also increased the level 
of 5-hydroxytryptamine (5HT) and tryptamine in 
the rat. 
-22-
f'letabolic PathTiJa.ys Investigated 
l 
transamination Indolepyruric acid 1 
decarboxylation 
Trytophan ------.".~ Try ptamine --;.. Indole-3-
MAO acetic acid 
1 (urinary excretion Hydroxylation dec, reased in depression) decarboxylation MAO 
5-hydroxytryptophan ;.r 5-hydroxytryptamine --+ 5-hydroxy-
(5 RTP) (A possible (5 HT) indole acetic 
defect (decreased in acid (5 HIAA) 
here?) depression} (reduced in 
(Abnormal Tryptophan metabolism 
is implicated in depression) 
In an initial investigation by Coppen, Shaw and 
Malleson, (1965) the rate of decarboxylation of 5-
spinal fluid 
in depression) 
h d ' t h (5 H'P'P) t: d' d 'b . tn' e ,y roxytryp op an _-'- ,'laS s .... u 1.e y me'~surlng 
expiratory rate of 14C02 following the injection of 
5 RTF labelled with 14C in the carboxyl group. The 
resu]ts showed that the rate of expiration of 14C02 
NBS reduced during depreSSion, probably because of a 
slower rate of decarboxylation of 5 RTP to form 5 HT. 
In a carefully controlled study by Coppen, Shail? l'lalleson, 
Eccleston, and Gundy (1965) tryptamine and IAA excretion 
was investigated in 13 severely depressed patients 
before and after recovery fro~ their illness. Urinary 
tryptamine excretion vlaS found to be abnormally 101'11" 
during the illness and rose by an average of 70% to 
Gtpproximately normal values after recovery. Urina.ry 
IAA showed no significant cha.nge. The findings WBre 
not related to urinary and volume, nor to diet. 
-2)-
Plasma try ptophan levels did not vary signif ican.tly. 
Unexpectedly. intravenous tryptamine given to depressed 
patien ts receiving IvLAO inh1 bi tors shovved that this 
procedure, unlike that with tryptophan, had no 
therapeutic effect. One explanation for this discrepancy 
W9S that tryptamine is inert in man or th9t a species 
difference in the blood-brain barrier exists between 
man and the smaller animals. 5-HTP, which passes the 
blood-brain barrier and reverses reserpine depression 
in small laboratory animals (Hess and Doepfner, 1961) 
also has little or no antidepressive action in man 
(Kline, Sacks, and Simpson, 1964).)) 5-HT and tryptamine 
are produced in the brain only from tryptophan. the 
most likely normal precursor of these amines in the 
CNS. 
An Alternative to the 
Catecholamine Hypothesis? 
The studies of Dewhurst and Marley (1964) with 
particular reference to the use of the young chick 
concluded that cerebral amines fall into two nain 
functional groups. Excitant (Type A) amines have the 
general formula R. CH2' CH2' NH2' where R is a fat-
soluble and planar hydrocarbon (e.g., indolyl or 
phenyl). All amines of this group produce all the 
phenomena of the alert state both behaviorally and 
physiologically with tryptamine being the most potent 
phYSiological agonist. Depressant (Type C) amines 
-2Lj,-
are of the general structure Hi. CH(OH). CH2. Nil. CR). 
h Hi· t 1 bl weret lS 1iliaer so u e (e.g •• catechol). Such amines 
produce all the phenomena of drowsiness or sleep, adren-
aline being the most potent physiologic agent. Type.A 
(excitant) or type C (depressant) activity depends primarily 
on lipid solubility and not on "whether a substance is an 
indole or catechol or ohenylethylamine. Dewhurst and 
Marley found that type A amines act through a specific 
receotor identical to the peripheral tryptamine receptor; 
type C amines are mediated by a receptor si~ilar to the 
peripheral alpha rece9tor. Thus, the known alerting 
effect of catecholamines has been shown to depend on 
hypertensive responses second"~Jry to stimulation of peri-
pheral alpha receptors. It has also been shown that a 
small group of amines (type B), which includes 5 HT, are 
biphasic, having the ability to act on both A and C 
receptors sequentially. Depressions, thus are related 
to a deficiency of type .A amines or ~alfunctions of the 
A receptor, vJhereas in 1'1ania the converse would be true. 34 
Objections to this hypothesis were raised by H. 
hreil-i'lalherbe of N.I.l'I.H. He states that Dewhurst's 
view of depressive psychosis is due to a deficiency of 
';type Ail amines, presumably tryptamine, and it must be 
inferred that tryptamine, has a role as a nervous 
transmitter. To sUbstantiate this it would be necessary 
to ShOVf that tryptamine. has been found in the normal 
brain; only small amounts vJ.ere found after combined 
-25-
administration of L-tryptophan and M80 inhibitors. 35 
The current concept of the alerting effect of brain 
catecholamines is based on the effects of dopa and 
dexa~phetamine. Dopa, which crosses the blood-brain 
barrier, is supposed to act as a precursor of brain 
dopamine and NEP; the action of amphetamine is also 
9ssumed to be indirect and mediated by dopamine and 
NEP. Dewhurst proposes a direct action for dopa 
and amphetamine. In doing so he overlooks t~e following; 
(1) the dopa effect is potentiated by MAO inhibitors and 
blocked by dec8rboxylase inhibitors (Carlsson, Lindquist. 
Magnusson, 1957); also, the alerting effect of a series of 
related amino acids is correlated with their rate of 
decarboxylation (Blascho and Chrusciel, 1960): (2) the 
central action of amphetamine is blocked when catecholamine 
synthesis is inhibited (Randnup, 1966). Similarly. the 
antidepressive action of impramine has been shown to 
depend on a 'lfifell-stocked store and normal synthesis of 
brain catecholamines (Sulser, Soroko, 1965). Whether 
the alerting effects of epinephrine and NEP are purely 
of peripheral origin is still controversial (Dell. 1960).35 
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